![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IL1RL1 |
Gene summary for IL1RL1 |
![]() |
Gene information | Species | Human | Gene symbol | IL1RL1 | Gene ID | 9173 |
Gene name | interleukin 1 receptor like 1 | |
Gene Alias | DER4 | |
Cytomap | 2q12.1 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q01638 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9173 | IL1RL1 | CA_HPV_1 | Human | Cervix | CC | 1.24e-19 | -5.36e-01 | 0.0264 |
9173 | IL1RL1 | CA_HPV_3 | Human | Cervix | CC | 1.91e-05 | -3.57e-01 | 0.0414 |
9173 | IL1RL1 | N_HPV_2 | Human | Cervix | N_HPV | 2.59e-05 | -3.72e-01 | -0.0131 |
9173 | IL1RL1 | CCI_1 | Human | Cervix | CC | 1.23e-03 | -5.79e-01 | 0.528 |
9173 | IL1RL1 | CCI_2 | Human | Cervix | CC | 3.50e-03 | -5.79e-01 | 0.5249 |
9173 | IL1RL1 | CCI_3 | Human | Cervix | CC | 1.82e-05 | -5.79e-01 | 0.516 |
9173 | IL1RL1 | CCII_1 | Human | Cervix | CC | 2.82e-08 | -5.79e-01 | 0.3249 |
9173 | IL1RL1 | Tumor | Human | Cervix | CC | 1.16e-23 | -5.79e-01 | 0.1241 |
9173 | IL1RL1 | sample1 | Human | Cervix | CC | 1.27e-06 | -5.79e-01 | 0.0959 |
9173 | IL1RL1 | sample3 | Human | Cervix | CC | 3.06e-19 | -5.51e-01 | 0.1387 |
9173 | IL1RL1 | H2 | Human | Cervix | HSIL_HPV | 8.15e-16 | -5.39e-01 | 0.0632 |
9173 | IL1RL1 | L1 | Human | Cervix | CC | 2.98e-09 | -5.79e-01 | 0.0802 |
9173 | IL1RL1 | T1 | Human | Cervix | CC | 2.01e-16 | -5.79e-01 | 0.0918 |
9173 | IL1RL1 | T2 | Human | Cervix | CC | 6.62e-03 | -5.79e-01 | 0.0709 |
9173 | IL1RL1 | T3 | Human | Cervix | CC | 2.48e-14 | -5.51e-01 | 0.1389 |
9173 | IL1RL1 | EOLP-1 | Human | Oral cavity | EOLP | 4.24e-11 | 5.44e-01 | -0.0202 |
9173 | IL1RL1 | EOLP-2 | Human | Oral cavity | EOLP | 2.15e-15 | 5.60e-01 | -0.0203 |
9173 | IL1RL1 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 2.31e-12 | -6.59e-01 | 0.02 |
9173 | IL1RL1 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 2.40e-10 | -6.59e-01 | 0.0267 |
9173 | IL1RL1 | PTCwithHT_6 | Human | Thyroid | HT | 4.35e-12 | -6.32e-01 | 0.02 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:00507294 | Cervix | CC | positive regulation of inflammatory response | 34/2311 | 142/18723 | 9.51e-05 | 1.25e-03 | 34 |
GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
GO:00508676 | Cervix | CC | positive regulation of cell activation | 73/2311 | 420/18723 | 1.50e-03 | 1.16e-02 | 73 |
GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
GO:00421163 | Cervix | CC | macrophage activation | 23/2311 | 106/18723 | 4.65e-03 | 2.81e-02 | 23 |
GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
GO:00022743 | Cervix | CC | myeloid leukocyte activation | 41/2311 | 223/18723 | 5.66e-03 | 3.25e-02 | 41 |
GO:0002822 | Cervix | CC | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/2311 | 168/18723 | 8.00e-03 | 4.18e-02 | 32 |
GO:000269611 | Cervix | HSIL_HPV | positive regulation of leukocyte activation | 44/737 | 409/18723 | 1.58e-09 | 3.04e-07 | 44 |
GO:005086711 | Cervix | HSIL_HPV | positive regulation of cell activation | 44/737 | 420/18723 | 3.59e-09 | 5.76e-07 | 44 |
GO:005072711 | Cervix | HSIL_HPV | regulation of inflammatory response | 41/737 | 386/18723 | 8.30e-09 | 1.03e-06 | 41 |
GO:000246011 | Cervix | HSIL_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 37/737 | 356/18723 | 7.84e-08 | 5.32e-06 | 37 |
GO:003210312 | Cervix | HSIL_HPV | positive regulation of response to external stimulus | 41/737 | 427/18723 | 1.40e-07 | 9.01e-06 | 41 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
IL33 | IL1RL1_IL1RAP | IL33_IL1RL1_IL1RAP | IL1 | HNSCC | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL1RL1 | SNV | Missense_Mutation | c.341N>A | p.Pro114Gln | p.P114Q | Q01638 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-49-4506-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
IL1RL1 | SNV | Missense_Mutation | rs753297060 | c.653N>A | p.Ala218Glu | p.A218E | Q01638 | protein_coding | tolerated(0.43) | benign(0.109) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL1RL1 | SNV | Missense_Mutation | novel | c.227N>A | p.Pro76Gln | p.P76Q | Q01638 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-50-6673-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL1RL1 | SNV | Missense_Mutation | novel | c.50N>T | p.Ala17Val | p.A17V | Q01638 | protein_coding | tolerated(0.81) | benign(0.025) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
IL1RL1 | SNV | Missense_Mutation | c.883G>C | p.Glu295Gln | p.E295Q | Q01638 | protein_coding | deleterious(0.01) | benign(0.315) | TCGA-86-A4P7-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IL1RL1 | SNV | Missense_Mutation | rs780029595 | c.351N>C | p.Leu117Phe | p.L117F | Q01638 | protein_coding | deleterious(0.05) | benign(0.142) | TCGA-91-6848-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | CR |
IL1RL1 | SNV | Missense_Mutation | c.1274N>A | p.Leu425Gln | p.L425Q | Q01638 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
IL1RL1 | SNV | Missense_Mutation | novel | c.1567C>A | p.Leu523Met | p.L523M | Q01638 | protein_coding | tolerated(0.18) | probably_damaging(0.981) | TCGA-97-7546-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Targeted Molecular therapy | tarceva | SD |
IL1RL1 | SNV | Missense_Mutation | c.655N>A | p.Gln219Lys | p.Q219K | Q01638 | protein_coding | tolerated(0.31) | benign(0.077) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD | |
IL1RL1 | SNV | Missense_Mutation | c.1144N>T | p.Val382Phe | p.V382F | Q01638 | protein_coding | deleterious(0) | benign(0.397) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |